BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 15383633)

  • 1. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
    Clark MJ; Traynor JR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization.
    Clark MJ; Neubig RR; Traynor JR
    J Pharmacol Exp Ther; 2004 Jul; 310(1):215-22. PubMed ID: 15014136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
    Xu H; Wang X; Wang J; Rothman RB
    Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
    Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
    Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation.
    Clark MJ; Furman CA; Gilson TD; Traynor JR
    J Pharmacol Exp Ther; 2006 May; 317(2):858-64. PubMed ID: 16436499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assays for G-protein-coupled receptor signaling using RGS-insensitive Galpha subunits.
    Clark MJ; Traynor JR
    Methods Enzymol; 2004; 389():155-69. PubMed ID: 15313565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model.
    Clark MJ; Linderman JJ; Traynor JR
    Mol Pharmacol; 2008 May; 73(5):1538-48. PubMed ID: 18285510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways.
    Clark MJ; Harrison C; Zhong H; Neubig RR; Traynor JR
    J Biol Chem; 2003 Mar; 278(11):9418-25. PubMed ID: 12524446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
    Puttfarcken PS; Werling LL; Cox BM
    Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteins.
    Rodríguez-Muñoz M; de la Torre-Madrid E; Sánchez-Blázquez P; Garzón J
    Mol Pain; 2007 Jul; 3():19. PubMed ID: 17634133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY; Friedman E; Olmstead MC; Burns LH
    Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.
    Talbot JN; Roman DL; Clark MJ; Roof RA; Tesmer JJ; Neubig RR; Traynor JR
    J Neurochem; 2010 Feb; 112(4):1026-34. PubMed ID: 20002516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
    Szücs M; Boda K; Gintzler AR
    J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
    Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation.
    Lopez-Gimenez JF; Vilaró MT; Milligan G
    Mol Pharmacol; 2008 Nov; 74(5):1278-91. PubMed ID: 18703670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term regulation of adenylyl cyclase activity by delta-opioid receptor are mediated by Galphai2 in neuroblastoma N2A cells.
    Zhang L; Tetrault J; Wang W; Loh HH; Law PY
    Mol Pharmacol; 2006 Jun; 69(6):1810-9. PubMed ID: 16525132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor endocytosis counteracts the development of opioid tolerance.
    Koch T; Widera A; Bartzsch K; Schulz S; Brandenburg LO; Wundrack N; Beyer A; Grecksch G; Höllt V
    Mol Pharmacol; 2005 Jan; 67(1):280-7. PubMed ID: 15475572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.
    Xu H; Lu YF; Rothman RB
    Synapse; 2003 Jan; 47(1):1-9. PubMed ID: 12422367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain.
    Chaipatikul V; Loh HH; Law PY
    J Pharmacol Exp Ther; 2003 Jun; 305(3):909-18. PubMed ID: 12626655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.